Finally, exemplifying requirements in many rare tumour types, the assessment, cross‐validation and definition of optimal methodologies for detection of specific biomarkers (e.g. MYC/N amplification, WNT subgroup status), including the relative performance of conventional and next‐generation technologies, is a critical requirement in their standardisation and clinical adoption. This evidence concerns the gene MYC and neoplasm.